NCT05058560 2025-03-13
Tislelizumab in Addition to BACE in Patients with NSCLC
The First Affiliated Hospital of Zhengzhou University
Phase 2 Completed
Clinical Trials
10 trialsNCT04691388 2024-12-05
A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor
Zhejiang Cancer Hospital
Phase 2 Completed
NCT03810066 2024-05-09
Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)
University Hospital, Essen
Phase 2 Completed
NCT03513666 2023-08-23
JS001
Shanghai Junshi Bioscience Co., Ltd.
Phase 2 Completed
NCT03812809 2022-05-19
A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive
Beta Pharma, Inc.
Phase 2 Completed
NCT03394118 2021-04-27
TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy
Asan Medical Center
Phase 2 Completed
NCT01941654 2020-06-18
ATOM_local Ablative Therapy
Chinese University of Hong Kong
Phase 2 Completed
NCT02976116 2019-11-15
A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer
Hutchmed
Phase 2 Completed
NCT00874848 2016-11-29
Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer
HiberCell, Inc.
Phase 2 Completed
NCT00655161 2014-01-29
A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation
GlobeImmune
Phase 2 Completed